Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 3
2023 3
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean de wilt j (530 results)?
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM, Tan NH, Rietdijk WJR, Geers D, Sablerolles RSG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Rugebregt S, Goorhuis A, Postma DF, Visser LG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, Haagmans BL, van Baarle D, Koopmans MPG; SWITCH-ON Research Group; van der Kuy PHM, GeurtsvanKessel CH, de Vries RD. Zaeck LM, et al. Nat Commun. 2024 May 18;15(1):4224. doi: 10.1038/s41467-024-48414-x. Nat Commun. 2024. PMID: 38762522 Free PMC article. Clinical Trial.
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, Schmitz KS, Garcia Garrido HM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Lafeber M, van Baarle D, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH Research Group. Sablerolles RSG, et al. N Engl J Med. 2022 Mar 10;386(10):951-963. doi: 10.1056/NEJMoa2116747. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045226 Free PMC article. Clinical Trial.
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.
van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, Jolink H, van de Veerdonk F, van Gorp ECM, de Wilt F, Bogers S, Gommers L, Geers D, Bruns AHW, Leavis HL, van Haga JW, Lemkes BA, van der Veen A, de Kruijf-Bazen SFJ, van Paassen P, de Leeuw K, van de Ven AAJM, Verbeek-Menken PH, van Wengen A, Arend SM, Ruten-Budde AJ, van der Ent MW, van Hagen PM, Sanders RW, Grobben M, van der Straten K, Burger JA, Poniman M, Nierkens S, van Gils MJ, de Vries RD, Dalm VASH. van Leeuwen LPM, et al. Among authors: de wilt f. J Allergy Clin Immunol. 2022 Jun;149(6):1949-1957. doi: 10.1016/j.jaci.2022.04.002. Epub 2022 Apr 11. J Allergy Clin Immunol. 2022. PMID: 35421449 Free PMC article. Clinical Trial.
Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.
van Leeuwen LPM, Grobben M, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, Jolink H, van de Veerdonk FL, van Gils MJ, de Vries RD, Dalm VASH; VACOPID Research Group. van Leeuwen LPM, et al. J Clin Immunol. 2023 Aug;43(6):1104-1117. doi: 10.1007/s10875-023-01514-7. Epub 2023 May 26. J Clin Immunol. 2023. PMID: 37231290 Free PMC article.
Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors.
Oosting SF, van der Veldt AAM, Fehrmann RSN, Bhattacharya A, van Binnendijk RS, GeurtsvanKessel CH, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, de Wilt F, Ernst SM, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. Oosting SF, et al. Among authors: de wilt f. ESMO Open. 2023 Aug;8(4):101599. doi: 10.1016/j.esmoop.2023.101599. Epub 2023 Jun 21. ESMO Open. 2023. PMID: 37450950 Free PMC article. No abstract available.
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment.
van der Veldt AAM, Oosting SF, Fehrmann RSN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, Hartog GD, Jalving M, Westphal TT, Bhattacharya A, de Wilt F, Ernst SM, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. van der Veldt AAM, et al. Among authors: de wilt f. ESMO Open. 2023 Feb;8(1):100785. doi: 10.1016/j.esmoop.2023.100785. Epub 2023 Jan 10. ESMO Open. 2023. PMID: 36764094 Free PMC article. No abstract available.
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours.
Oosting SF, van der Veldt AAM, Fehrmann RSN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, Bhattacharya A, de Wilt F, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. Oosting SF, et al. Among authors: de wilt f. Lancet Oncol. 2022 Jul;23(7):833-835. doi: 10.1016/S1470-2045(22)00203-0. Epub 2022 Apr 25. Lancet Oncol. 2022. PMID: 35483383 Free PMC article. No abstract available.
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
van Leeuwen LPM, Grobben M, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, Jolink H, van de Veerdonk FL, van Gils MJ, de Vries RD, Dalm VASH; VACOPID Research Group. van Leeuwen LPM, et al. Front Immunol. 2024 Apr 18;15:1390022. doi: 10.3389/fimmu.2024.1390022. eCollection 2024. Front Immunol. 2024. PMID: 38698851 Free PMC article.